ArticleRSC advances2026
MRI tumor imaging by click chemistry using Gd(iii)-DOTA-DBCO and Ac
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic resonance imaging (MRI) is an important diagnostic tool widely used in clinical practice. It does not involve harmful ionizing radiation, allowing for more frequent or long-term imaging. However, MRI suffers from limited sensitivity, and contrast agents are often required to enhance signal intensity and image contrast. In particular, tumors cannot always be clearly distinguished from surrounding tissues. Therefore, one potential strategy to improve MRI for cancer diagnosis is to enable tumor-specific detection. In this study, we synthesized a novel MRI contrast agent by conjugating a gadolinium(iii)-DOTA complex with dibenzocyclooctyne (DBCO). An azide-modified mannosamine derivative was employed for metabolic glycoengineering, enabling the expression of chemical tags on cancer cell surfaces. These tags undergo a bioorthogonal click reaction with the functionalized gadolinium(iii)-DOTA complex, facilitating rapid and sensitive enhancement of MRI contrast for imaging of cancer cells both
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.